What is Pulmonary Alveolar Proteinosis?
Pulmonary alveolar proteinosis (PAP) is a rare syndrome caused by accumulation of surfactant-derived lipoproteinaceous material in the alveoli, leading to progressive dyspnea, hypoxemia, and risk of respiratory failure and early death. 1
Pathophysiology
PAP results from impaired surfactant clearance or abnormal surfactant production 1. The disease is characterized by:
- Accumulation of surfactant lipoproteins within alveolar spaces
- Progressive hypoxemic respiratory insufficiency or failure
- Increased risk of secondary infections and/or pulmonary fibrosis 1
The key pathophysiologic mechanism involves disruption of granulocyte-macrophage colony-stimulating factor (GM-CSF) signaling, which is essential for alveolar macrophage maturation and surfactant catabolism 2.
Classification: Three Mechanistically Distinct Forms
Primary PAP
- Driven by disruption of GM-CSF signaling resulting in dysfunctional alveolar macrophages and neutrophils 1
- Autoimmune PAP: Caused by neutralizing anti-GM-CSF autoantibodies; represents approximately 90% of all adult PAP cases 2, 3
- Hereditary PAP: Results from mutations in genes encoding GM-CSF receptor 1
Secondary PAP
- Occurs due to underlying diseases or conditions that reduce the numbers and/or functions of alveolar macrophages 1
- Associated with various conditions affecting macrophage function
Congenital PAP (Pulmonary Surfactant Metabolic Dysfunction Disorders)
- Caused by mutations in genes encoding surfactant proteins or genes involved in surfactant production or lung development 1
- Can manifest as acute or progressive respiratory failure, including premature death within the first days of life in neonates 3
Epidemiology
The prevalence of autoimmune PAP is estimated at 6.7-6.9 per million in the general population 1.
Clinical Manifestations
Clinical presentations range widely:
- Insidious onset with progressive dyspnea
- Acute respiratory failure
- Some patients remain asymptomatic
- 10-15% of patients develop respiratory failure 4
- Hypoxemia triggered by exertion
- Cough 4
Diagnostic Approach
The diagnosis of PAP is based on CT and BAL cytology or lung histology 1. The diagnostic workup includes:
Imaging
- High-resolution chest computed tomography (CT) showing characteristic "crazy-paving" pattern 1
Laboratory Testing
- GM-CSF antibody testing: The serum level of GM-CSF autoantibody is the only disease-specific biomarker of autoimmune PAP 5
- Elevated serum GM-CSF levels in patients with normal GM-CSF autoantibody levels is highly suspicious for hereditary PAP 5
- Genetic testing for suspected hereditary or congenital forms 1
Invasive Procedures
- Bronchoalveolar lavage (BAL) with cytology
- Lung biopsy (when necessary) 1
Pulmonary Function Testing
- Assessment of gas exchange impairment
- Diffusing capacity of the lung for carbon monoxide (DLCO)
- Arterial blood gas analysis 1
Management Options
Whole lung lavage (WLL) is considered the main treatment for many, but not all, PAP-causing diseases 1. Treatment is focused on removing the proteinaceous material and includes:
First-Line Therapy
- Whole lung lavage (WLL): Current gold standard of care 3
GM-CSF Augmentation Therapy
- Inhaled GM-CSF appears to be a promising option for autoimmune PAP 1
- Supplemental GM-CSF is useful, though details about indications, choice of agent, and dosing remain unclear 2
Refractory Cases
- Rituximab: For treatment-resistant autoimmune PAP 1
- Plasmapheresis: For severe refractory cases 1
- Lung transplantation: Reserved for end-stage disease unresponsive to other therapies 1
Important Clinical Caveats
- Treatment approach depends on the pathogenic form and disease severity 3
- Supporting evidence for therapies remains limited 1
- The serum GM-CSF autoantibody level does not correlate with disease severity 5
- Early diagnosis and intervention are crucial for improving patient outcomes 6
- Pulmonary fibrosis occurs occasionally in patients with PAP 2